Cargando…

Prognostic value and therapeutic potential of the long noncoding RNA TP73-AS1 in cancers: A systematic review and meta-analysis

Studies published in recent years have demonstrated that abnormal long noncoding RNA (lncRNA) antisense RNA to TP73 gene (TP73-AS1) expression is markedly associated with tumorigenesis, cancer progression and the prognosis of cancer patients. We aimed to explore the prognostic value of TP73-AS1 in m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Yuan, Zhao, Meng, Yu, Yang, Li, Quanpeng, Wang, Fei, Wu, Peiyao, Zhang, Wen, Miao, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271165/
https://www.ncbi.nlm.nih.gov/pubmed/32493915
http://dx.doi.org/10.1038/s41598-020-65726-2
_version_ 1783542038065577984
author Zhong, Yuan
Zhao, Meng
Yu, Yang
Li, Quanpeng
Wang, Fei
Wu, Peiyao
Zhang, Wen
Miao, Lin
author_facet Zhong, Yuan
Zhao, Meng
Yu, Yang
Li, Quanpeng
Wang, Fei
Wu, Peiyao
Zhang, Wen
Miao, Lin
author_sort Zhong, Yuan
collection PubMed
description Studies published in recent years have demonstrated that abnormal long noncoding RNA (lncRNA) antisense RNA to TP73 gene (TP73-AS1) expression is markedly associated with tumorigenesis, cancer progression and the prognosis of cancer patients. We aimed to explore the prognostic value of TP73-AS1 in multiple cancers. We comprehensively searched PubMed, Embase, Web of Science and the Cochrane Library (up to February 21, 2019). Hazard ratios (HRs), odds ratios (ORs) and the corresponding 95% confidence intervals (95% CIs) were calculated to estimate the association of TP73-AS1 with survival and clinicopathological features. The potential targets and pathways of TP73-AS1 in multiple cancers were summarized. Nineteen studies that involved thirteen types of cancers and 1329 cancer patients were identified as eligible for this meta-analysis. The results showed that high TP73-AS1 expression was significantly correlated with shorter overall survival (OS) (HR = 1.962, 95% CI 1.630-2.362) and disease-free survival (DFS) (HR = 2.050, 95% CI 1.293-3.249). The summary HRs of OS were 2.101 (95% CI 1.516-2.911) for gastric cancer (GC) and 1.920 (95% CI 1.253-2.942) for osteosarcoma. Subgroup analysis of OS demonstrated that the differential expression of TP73-AS1 in cancer tissues was a potential source of heterogeneity. Furthermore, increased TP73-AS1 expression was markedly associated with larger tumor size (OR = 2.759, 95% CI 1.759-4.330), advanced histological grade (OR = 2.394, 95% CI 1.231-4.656), lymph node metastasis (OR = 2.687, 95% CI 1.211-5.962), distant metastasis (OR = 4.145, 95% CI 2.252-7.629) and advanced TNM stage (OR = 2.633, 95% CI 1.507-4.601). The results of Egger’s test and sensitivity analysis verified the robustness of the original results. High TP73-AS1 expression can predict poor survival and poor clinicopathological features in cancer patients and TP73-AS1 might be a potential biomarker and therapeutic target.
format Online
Article
Text
id pubmed-7271165
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-72711652020-06-05 Prognostic value and therapeutic potential of the long noncoding RNA TP73-AS1 in cancers: A systematic review and meta-analysis Zhong, Yuan Zhao, Meng Yu, Yang Li, Quanpeng Wang, Fei Wu, Peiyao Zhang, Wen Miao, Lin Sci Rep Article Studies published in recent years have demonstrated that abnormal long noncoding RNA (lncRNA) antisense RNA to TP73 gene (TP73-AS1) expression is markedly associated with tumorigenesis, cancer progression and the prognosis of cancer patients. We aimed to explore the prognostic value of TP73-AS1 in multiple cancers. We comprehensively searched PubMed, Embase, Web of Science and the Cochrane Library (up to February 21, 2019). Hazard ratios (HRs), odds ratios (ORs) and the corresponding 95% confidence intervals (95% CIs) were calculated to estimate the association of TP73-AS1 with survival and clinicopathological features. The potential targets and pathways of TP73-AS1 in multiple cancers were summarized. Nineteen studies that involved thirteen types of cancers and 1329 cancer patients were identified as eligible for this meta-analysis. The results showed that high TP73-AS1 expression was significantly correlated with shorter overall survival (OS) (HR = 1.962, 95% CI 1.630-2.362) and disease-free survival (DFS) (HR = 2.050, 95% CI 1.293-3.249). The summary HRs of OS were 2.101 (95% CI 1.516-2.911) for gastric cancer (GC) and 1.920 (95% CI 1.253-2.942) for osteosarcoma. Subgroup analysis of OS demonstrated that the differential expression of TP73-AS1 in cancer tissues was a potential source of heterogeneity. Furthermore, increased TP73-AS1 expression was markedly associated with larger tumor size (OR = 2.759, 95% CI 1.759-4.330), advanced histological grade (OR = 2.394, 95% CI 1.231-4.656), lymph node metastasis (OR = 2.687, 95% CI 1.211-5.962), distant metastasis (OR = 4.145, 95% CI 2.252-7.629) and advanced TNM stage (OR = 2.633, 95% CI 1.507-4.601). The results of Egger’s test and sensitivity analysis verified the robustness of the original results. High TP73-AS1 expression can predict poor survival and poor clinicopathological features in cancer patients and TP73-AS1 might be a potential biomarker and therapeutic target. Nature Publishing Group UK 2020-06-03 /pmc/articles/PMC7271165/ /pubmed/32493915 http://dx.doi.org/10.1038/s41598-020-65726-2 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Zhong, Yuan
Zhao, Meng
Yu, Yang
Li, Quanpeng
Wang, Fei
Wu, Peiyao
Zhang, Wen
Miao, Lin
Prognostic value and therapeutic potential of the long noncoding RNA TP73-AS1 in cancers: A systematic review and meta-analysis
title Prognostic value and therapeutic potential of the long noncoding RNA TP73-AS1 in cancers: A systematic review and meta-analysis
title_full Prognostic value and therapeutic potential of the long noncoding RNA TP73-AS1 in cancers: A systematic review and meta-analysis
title_fullStr Prognostic value and therapeutic potential of the long noncoding RNA TP73-AS1 in cancers: A systematic review and meta-analysis
title_full_unstemmed Prognostic value and therapeutic potential of the long noncoding RNA TP73-AS1 in cancers: A systematic review and meta-analysis
title_short Prognostic value and therapeutic potential of the long noncoding RNA TP73-AS1 in cancers: A systematic review and meta-analysis
title_sort prognostic value and therapeutic potential of the long noncoding rna tp73-as1 in cancers: a systematic review and meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271165/
https://www.ncbi.nlm.nih.gov/pubmed/32493915
http://dx.doi.org/10.1038/s41598-020-65726-2
work_keys_str_mv AT zhongyuan prognosticvalueandtherapeuticpotentialofthelongnoncodingrnatp73as1incancersasystematicreviewandmetaanalysis
AT zhaomeng prognosticvalueandtherapeuticpotentialofthelongnoncodingrnatp73as1incancersasystematicreviewandmetaanalysis
AT yuyang prognosticvalueandtherapeuticpotentialofthelongnoncodingrnatp73as1incancersasystematicreviewandmetaanalysis
AT liquanpeng prognosticvalueandtherapeuticpotentialofthelongnoncodingrnatp73as1incancersasystematicreviewandmetaanalysis
AT wangfei prognosticvalueandtherapeuticpotentialofthelongnoncodingrnatp73as1incancersasystematicreviewandmetaanalysis
AT wupeiyao prognosticvalueandtherapeuticpotentialofthelongnoncodingrnatp73as1incancersasystematicreviewandmetaanalysis
AT zhangwen prognosticvalueandtherapeuticpotentialofthelongnoncodingrnatp73as1incancersasystematicreviewandmetaanalysis
AT miaolin prognosticvalueandtherapeuticpotentialofthelongnoncodingrnatp73as1incancersasystematicreviewandmetaanalysis